DE19906615A1 - Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung - Google Patents
Peptid-Varianten des Tumormarkers MUC1 und ihre VerwendungInfo
- Publication number
- DE19906615A1 DE19906615A1 DE19906615A DE19906615A DE19906615A1 DE 19906615 A1 DE19906615 A1 DE 19906615A1 DE 19906615 A DE19906615 A DE 19906615A DE 19906615 A DE19906615 A DE 19906615A DE 19906615 A1 DE19906615 A1 DE 19906615A1
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- muc1
- vntr
- peptide variants
- pap20
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 35
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 title claims abstract description 17
- 102100034256 Mucin-1 Human genes 0.000 title claims abstract description 17
- 239000000439 tumor marker Substances 0.000 title abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 6
- 230000002163 immunogen Effects 0.000 claims abstract description 4
- 230000000890 antigenic effect Effects 0.000 claims abstract description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 229960005486 vaccine Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 108020001019 DNA Primers Proteins 0.000 claims 1
- 239000003155 DNA primer Substances 0.000 claims 1
- 230000003327 cancerostatic effect Effects 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 230000009946 DNA mutation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 230000002032 cellular defenses Effects 0.000 description 1
- 108090001092 clostripain Proteins 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906615A DE19906615A1 (de) | 1999-02-17 | 1999-02-17 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| DK00916753T DK1151005T3 (da) | 1999-02-17 | 2000-02-17 | Peptidvarianter af tumormarkør MUC1 og deres anvendelse |
| JP2000599782A JP2002541067A (ja) | 1999-02-17 | 2000-02-17 | 腫瘍マーカーｍｕｃ１のペプチド変異体及びその利用 |
| CA002368309A CA2368309A1 (en) | 1999-02-17 | 2000-02-17 | Peptide variants of the tumour marker muc1 and the use thereof |
| PCT/DE2000/000440 WO2000049045A1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
| EP00916753A EP1151005B1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
| DE50002584T DE50002584D1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
| AT00916753T ATE243222T1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
| ES00916753T ES2200851T3 (es) | 1999-02-17 | 2000-02-17 | Variantes de peptido del marcador tumoral muc1 y su utilizacion. |
| AU38013/00A AU772709B2 (en) | 1999-02-17 | 2000-02-17 | Peptide variants of the tumour marker MUC1 and the use thereof |
| DE2000132402 DE10032402A1 (de) | 1999-02-17 | 2000-07-06 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| US09/931,638 US20090054622A1 (en) | 1999-02-17 | 2001-08-16 | Peptide variants of the tumor marker MUC1 and their application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19906615A DE19906615A1 (de) | 1999-02-17 | 1999-02-17 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE19906615A1 true DE19906615A1 (de) | 2000-09-28 |
Family
ID=7897778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19906615A Withdrawn DE19906615A1 (de) | 1999-02-17 | 1999-02-17 | Peptid-Varianten des Tumormarkers MUC1 und ihre Verwendung |
| DE50002584T Expired - Fee Related DE50002584D1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE50002584T Expired - Fee Related DE50002584D1 (de) | 1999-02-17 | 2000-02-17 | Peptid-varianten des tumormarkers muc1 und ihre verwendung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090054622A1 (enExample) |
| EP (1) | EP1151005B1 (enExample) |
| JP (1) | JP2002541067A (enExample) |
| AT (1) | ATE243222T1 (enExample) |
| AU (1) | AU772709B2 (enExample) |
| CA (1) | CA2368309A1 (enExample) |
| DE (2) | DE19906615A1 (enExample) |
| DK (1) | DK1151005T3 (enExample) |
| ES (1) | ES2200851T3 (enExample) |
| WO (1) | WO2000049045A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003266236A1 (en) | 2002-07-22 | 2004-02-09 | Nemod Immuntherapie Ag | Method for the production of an immunostimulating mucin (muc1) |
| US9346867B2 (en) | 2010-04-19 | 2016-05-24 | Sumitomo Bakelite Co., Ltd. | Cancer-related glycopeptide epitopes, antibodies and methods of use |
| KR102049928B1 (ko) | 2011-08-17 | 2019-11-28 | 글로브이뮨 | 효모-muc1 면역요법 조성물 및 그 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3023469B2 (ja) * | 1992-02-21 | 2000-03-21 | 株式会社日本抗体研究所 | 糖タンパク質３９遺伝子 |
| US6120765A (en) * | 1993-04-02 | 2000-09-19 | Shiseido Co. Ltd. | Urokinase plasminogen activator fragments |
| US5744144A (en) * | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| AU727308B2 (en) * | 1997-02-24 | 2000-12-07 | Dana-Farber Cancer Institute | Recombinant pox virus for immunization against muc1 tumor-associated antigen |
-
1999
- 1999-02-17 DE DE19906615A patent/DE19906615A1/de not_active Withdrawn
-
2000
- 2000-02-17 CA CA002368309A patent/CA2368309A1/en not_active Abandoned
- 2000-02-17 WO PCT/DE2000/000440 patent/WO2000049045A1/de not_active Ceased
- 2000-02-17 DK DK00916753T patent/DK1151005T3/da active
- 2000-02-17 DE DE50002584T patent/DE50002584D1/de not_active Expired - Fee Related
- 2000-02-17 AT AT00916753T patent/ATE243222T1/de not_active IP Right Cessation
- 2000-02-17 AU AU38013/00A patent/AU772709B2/en not_active Ceased
- 2000-02-17 JP JP2000599782A patent/JP2002541067A/ja active Pending
- 2000-02-17 EP EP00916753A patent/EP1151005B1/de not_active Expired - Lifetime
- 2000-02-17 ES ES00916753T patent/ES2200851T3/es not_active Expired - Lifetime
-
2001
- 2001-08-16 US US09/931,638 patent/US20090054622A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1151005T3 (da) | 2003-10-13 |
| ATE243222T1 (de) | 2003-07-15 |
| DE50002584D1 (de) | 2003-07-24 |
| CA2368309A1 (en) | 2000-08-24 |
| AU772709B2 (en) | 2004-05-06 |
| EP1151005A1 (de) | 2001-11-07 |
| ES2200851T3 (es) | 2004-03-16 |
| JP2002541067A (ja) | 2002-12-03 |
| AU3801300A (en) | 2000-09-04 |
| US20090054622A1 (en) | 2009-02-26 |
| EP1151005B1 (de) | 2003-06-18 |
| WO2000049045A1 (de) | 2000-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69727966T2 (de) | Ein mit krebs assoziiertes antigen kodierendes isoliertes nukleinsäuremolekül, das antigen selbst, und dessen verwendungen | |
| DE69526339T2 (de) | Monoklonale antikörper, die an den vorläufer des tumorabstossantigen mage-1 anbinden, rekombinantes mage-1, und von mage-1 abgebieteteimmunogene peptide | |
| DE69630890T2 (de) | Peptid-immitierende substanzen in der krebstherapie | |
| EP2400018B1 (de) | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung | |
| DE69434324T2 (de) | Mucin-Mannan-Konjugate und ihre immunotherapeutische Anwendung | |
| DE69032922T2 (de) | Menschliches intra-akrosomales spermaantigen zur verwendung in einem empfängnisverhütungsimpfstoff | |
| DE3650242T2 (de) | Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen. | |
| EP2371848B1 (de) | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung | |
| DE69931482T2 (de) | Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| DE68926916T2 (de) | 14-Beta-gal Sauger-Lectin | |
| EP1483389A2 (de) | Differentiell in tumoren exprimierte genprodukte und deren verwendung | |
| EP1349933A2 (de) | Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen | |
| DE3687071T2 (de) | Malaria-impfstoff. | |
| DE69532874T2 (de) | RPDL Protein und kodierende DNS | |
| DE69735591T2 (de) | Impfstoff auf einem plasmid beruhend zur behandlung von atherosclerosis | |
| DE60029953T2 (de) | Spezifische Antikörper gegen humanes Choriongonadotropin und deren Verwendung in Therapie und Diagnose | |
| EP1151005B1 (de) | Peptid-varianten des tumormarkers muc1 und ihre verwendung | |
| AT505574A1 (de) | Pharmazeutische zusammensetzung | |
| DE19936563A1 (de) | Tumorassoziiertes Antigen | |
| WO2006000213A9 (de) | Peptide zur inhibition der interaktion von proteinkinase a und proteinkinase a-ankerproteinen | |
| DE3933850A1 (de) | Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins | |
| DE69736820T2 (de) | Mäuse Adhesions Molekül Occludin | |
| DE19924199A1 (de) | Tumorassoziiertes Antigen | |
| DE602004001395T2 (de) | Rhesus-karzinoembryonales antigen, dieses codierende nukleotide und verwendungen davon | |
| DE3650641T2 (de) | Peptidfragment des menschlichen Villins und Antikörper dagegen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AF | Is addition to no. |
Ref document number: 10032402 Country of ref document: DE |
|
| 8127 | New person/name/address of the applicant |
Owner name: CELL CENTER COLOGNE GMBH, 50931 KOELN, DE |
|
| 8139 | Disposal/non-payment of the annual fee |